000 01713cam  2200397zi 4500
0019.901130
003CaOODSP
00520221107175608
006m     o  d f      
007cr cn|||||||||
008210625e202107  onc     ob   f000 0 eng d
020 |a9780660393704
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-277/2021E-1-PDF
24500|aGuidance document : |bmanagement of drug submissions and applications.
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cJuly 2021.
264 4|c©2021
300 |a1 online resource (72 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Ligne directrice : gestion des présentations et des demandes de drogue.
500 |aThe PDF copy has been replaced (2022-01-26) with an amended version as requested by the publisher.
500 |a"Pub.: 210144."
500 |aIssued also in HTML format.
504 |aIncludes bibliographical references.
650 0|aDrug approval|zCanada.
650 0|aPharmaceutical policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLignes directrice : |w(CaOODSP)9.901132
794 |tGuidance document : |w(CaOODSP)9.912786
795 |tGuidance document : |w(CaOODSP)9.896428
85640|qPDF|s686 KB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H164-277-2021-eng-1.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/management-drug-submissions/industry/document.html